Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
11 search results for:

Daratumumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 30-06-2016 | Multiple myeloma | Article

    Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

    The authors evaluate the latest clinical trials on the use of daratumumab as a single agent and in combination regimens for the treatment of multiple myeloma. Sanchez L et al. J Hematol Oncol 2016; 9: 51. doi:10.1186/s13045-016-0283-0

  2. 25-11-2021 | Multiple myeloma | Adis Journal Club | Article
    Clinical Drug Investigation

    Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

    Methods An external control arm for CARTITUDE-1 was created from patients in the long-term follow-up for three clinical trials of daratumumab (POLLUX, CASTOR, and EQUULEUS) who satisfied the eligibility criteria of CARTITUDE-1.

  3. 16-02-2017 | Multiple myeloma | Article

    Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience

    This articles reviews the clinical efficacy of immunomodulatory drugs, their structure-function relationship, molecular mechanisms of action, and associated second primary malignancies and thrombosis. Holstein SA & McCarthy PL. Drugs 2017; 77: 505–520. doi:10.1007/s40265-017-0689-1

  4. 10-01-2017 | Multiple myeloma | Article

    Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity

    A comprehensive overview of the latest updates in 2016 and a prospective look towards the therapeutic landscape in 2017 for patients with multiple myeloma.  Nat Rev Clin Oncol 2017; 14: 73–74. doi:10.1038/nrclinonc.2016.221

    Author:
    Prashant Kapoor, S. Vincent Rajkumar
  5. 27-09-2016 | Multiple myeloma | Article

    The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

    An expert review of current treatment options for relapsed/refractory multiple myeloma, the mechanism of action of panobinostat, and how panobinostat fits into the current therapeutic landscape. San-Miguel JF, Einsele H, & Moreau P. Adv Ther 2016; 33: 1896–1920. doi:10.1007/s12325-016-0413-7

  6. 04-01-2016 | Treatment | Article

    Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

    NCT01239797, phase III Lenalidomide, dexamethasone Daratumumab Anti-CD38 i.v.

    Author:
    R F Cornell, A A Kassim
  7. 17-08-2016 | Hematologic cancers | Article

    Genomic complexity of multiple myeloma and its clinical implications

    Specifically, whether treatments such as the anti-CD319 antibody elotuzumab 112, 113 , the anti-CD38 antibodies daratumumab 114, 115 , chimeric antigen receptor (CAR) T cells (directed against B-cell maturation antigen (BCMA) 116 or the immunoglobulin κ light chain 117 ) or immune-checkpoint inhibitors (nivolumab 118 and atezolizumab 119 ), will be effective regardless of the genomic characteristics of the tumour, and the effect of these strategies on clonal selection remains to be explored.

    Author:
    Saloman Manier, Karma Z. Salem, Jihye Park, Dan A. Landau, Gad Getz, Irene M. Ghobrial
  8. 30-06-2016 | Multiple myeloma | Article

    Novel agents in the treatment of multiple myeloma: a review about the future

    The authors review the plethora of novel agents currently in development or recently approved for the treatment of patients with multiple myeloma. Naymagon L & Abdul-Hay M. J Hematol Oncol 2016; 9: 52. doi:10.1186/s13045-016-0282-1

  9. 19-02-2016 | Treatment | Article

    Smoldering multiple myeloma: emerging concepts and therapeutics

    This review focuses on advances in the smoldering multiple myeloma risk-stratification model and recent clinical trials in this patient population. Sundararajan S, Kumar A, Korde N, Agarwal A. Curr Hematol Malig Rep  2016; 11: 102–110. doi: 10.1007/s11899-016-0305-6

  10. 22-01-2016 | Treatment | Article

    Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies

    Here, Guillerey et al. review the immunological microenvironment in myeloma and highlight the numerous promising immune-targeting strategies approved or in clinical trials for the treatment of myeloma. Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ.  Cell Mol Life Sci  2016; 73:1569–1589. doi: 10.1007/s00018-016-2135-z

  11. 03-02-2015 | Treatment | Article

    Treatment-related symptom management in patients with multiple myeloma: a review

    This review discusses current multiple myeloma treatment options, effective symptom management approaches, and practical strategies for supportive care. Colson K. Support Care Cancer 2015; 23: 1431–1445. doi:10.1007/s00520-014-2552-1

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.